EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Delayed and selective bone health assessment following cancer diagnosis: a real-world gap in survivorship care

Vanessa Rouach, Ziv Versano, Meital Sasson, Yona Greenman, Arnon Makori

Supportive Care in Cancer · 2026-11 · 34 (11)

DOI: 10.1007/s00520-026-11340-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Supportive Care in Cancer, online erschienen am 19.10.2026. Verfasst von Vanessa Rouach und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Endocrinology, Metabolism and Hypertension, Tel Aviv Sourasky University Medical Center, Tel Aviv, Israel. vanessar@tlvmc.gov.il. Hauptthemen laut MEDLINE: Bone Density, Absorptiometry, Photon, Neoplasms, Osteoporosis. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cancer treatment–induced bone loss (CTIBL) is well-recognized in hormone-sensitive malignancies such as breast and prostate cancer but is less consistently implemented in patients with other solid tumors and hematologic malignancies. Furthermore, the long-term skeletal effects of newer systemic therapies, including immune checkpoint inhibitors and targeted agents, remain incompletely characterized. Although bone mineral density (BMD) assessment by dual-energy X-ray absorptiometry (DXA) is recommended for patients at increased skeletal risk, real-world utilization patterns remain poorly characterized.

Objectives

To evaluate DXA utilization, timing, BMD results, and associated clinical characteristics following a new cancer diagnosis in a large real-world cohort.

Methods

We conducted a retrospective cohort study using the MDClone platform, including adults with a first cancer diagnosis between January 1, 2015, and December 31, 2024, treated at Assuta Medical Centers in Israel. DXA completion, timing, BMD and T -scores, and prevalence of osteopenia and osteoporosis were analyzed.

Results

Among 21,112 patients with newly diagnosed cancer (77.0% women; mean age 60.2 ± 13.1 years), 7496 (35.5%) underwent DXA at any time following diagnosis. DXA utilization was significantly lower in men than in women (15.0% vs. 41.7%). Early DXA assessment within 6 months of diagnosis was uncommon (1550 patients; 7.3% of the total cohort), and only 14.1% underwent DXA within the first 12 months. Median time from cancer diagnosis to DXA was 14.8 months. DXA utilization varied by cancer type and was highest in breast cancer (42.2%) and prostate cancer (30.0%), with substantially lower utilization among patients with other malignancies. Among patients with complete evaluable measurements, 40.2% had normal BMD, 45.2% had osteopenia, and 14.5% met criteria for osteoporosis.

Conclusions

In our real-world experience within a large private healthcare network, DXA assessment after cancer diagnosis is infrequently performed and often delayed, with marked disparities by sex and cancer type. A substantial burden of low bone mass is already present at the time of evaluation, highlighting missed opportunities for early skeletal risk identification.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bone DensityAbsorptiometry, PhotonNeoplasmsOsteoporosisBone Diseases, MetabolicHumansMaleRetrospective StudiesMiddle AgedFemaleAgedTime FactorsIsraelSurvivorshipAdultCohort StudiesPrevalence

Stichwörter der Autor:innen

Bone mineral densityCancer treatment–induced bone loss (CTIBL)Dual X-ray absorptiometry (DXA)Fracture preventionOsteopeniaOsteoporosis

Autor:innen und Institutionen

  • Institute of Endocrinology, Metabolism and Hypertension, Tel Aviv Sourasky University Medical Center, Tel Aviv, Israel. vanessar@tlvmc.gov.il.
  • Gray School of Medicine, The Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel. vanessar@tlvmc.gov.il.
  • Assuta Medical Centers, Tel Aviv, Israel. vanessar@tlvmc.gov.il.
  • Assuta Medical Centers, Tel Aviv, Israel.
  • Institute of Endocrinology, Metabolism and Hypertension, Tel Aviv Sourasky University Medical Center, Tel Aviv, Israel.
  • Gray School of Medicine, The Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.

Zitieren

APA

Rouach, V., Versano, Z., Sasson, M., Greenman, Y., & Makori, A. (2026). Delayed and selective bone health assessment following cancer diagnosis: a real-world gap in survivorship care. Supportive Care in Cancer, 34(11). https://doi.org/10.1007/s00520-026-11340-3

Vancouver

Rouach V, Versano Z, Sasson M, Greenman Y, Makori A. Delayed and selective bone health assessment following cancer diagnosis: a real-world gap in survivorship care. Supportive Care in Cancer. 2026;34(11). doi:10.1007/s00520-026-11340-3

BibTeX
@article{Rouach2026,
  author = {Rouach, Vanessa and Versano, Ziv and Sasson, Meital and Greenman, Yona and Makori, Arnon},
  title = {Delayed and selective bone health assessment following cancer diagnosis: a real-world gap in survivorship care},
  journal = {Supportive Care in Cancer},
  year = {2026},
  volume = {34},
  number = {11},
  doi = {10.1007/s00520-026-11340-3}
}
Kostenlos starten →